Evidence for schizophrenia as a disorder of neuroplasticity

American Journal of Psychiatry

Volumn 172, Issue 4, 2015, Pages 312-313

  McCullumsmith, Robert E ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUTAMATE DECARBOXYLASE 67; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; DLG4 PROTEIN, HUMAN; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; SIGNAL PEPTIDE;

AUTOPSY; DISEASE ASSOCIATION; EDITORIAL; ENZYME ACTIVITY; GENETIC RISK; HIPPOCAMPAL CA3 REGION; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING; HIPPOCAMPAL CA1 REGION; METABOLISM;

CA1 REGION, HIPPOCAMPAL; CA3 REGION, HIPPOCAMPAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84926012944     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15010069     Document Type: Editorial

References (16)

1. GordonMW:Neuronal plasticityandmemory.AmJ Orthopsychiatry 1969; 39:578-594
2. Malenka RC, Nicoll RA: Long-term potentiation: a decade of progress? Science 1999; 285:1870-1874
3. Smythies J: The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res 2002; 4:147-150
4. LiW,Ghose S, Gleason K, et al: Synaptic proteins in the hippocampus indicative of increased neuronal activity inCA3in schizophrenia.Am J Psychiatry 2015; 172:373-382
5. BenesFM:Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry 1999; 46:589-599
6. Harrison PJ: The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004; 174:151-162
7. McCullumsmith RE,HammondJH, Shan D, et al: Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology 2014; 39:65-87
8. Belotti E, Polanowska J, Daulat AM, et al: The human PDZome: a gateway to PSD95-Disc large-zonula occludens (PDZ)-mediated functions. Mol Cell Proteomics 2013; 12:2587-2603
9. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308
10. Young CE, Arima K, Xie J, et al: SNAP-25 deficit and hippocampal connectivity in schizophrenia. Cereb Cortex 1998; 8:261-268
11. Eastwood SL, Harrison PJ: Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 2005; 73:159-172
12. McGuire JL,HammondJH, Yates SD, et al: Altered serine/threonine kinase activity in schizophrenia. Brain Res 2014; 1568:42-54
13. Wible CG: Hippocampal physiology, structure, and function and the neuroscience of schizophrenia: a unified account of declarative memory deficits, working memory deficits, and schizophrenic symptoms. Behav Sci (Basel) 2013; 3:298-315
14. Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421-427
15. Arnedo J, Svrakic DM, Del Val C, et al: Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independentgenome-wide association studies.AmJ Psychiatry 2015; 172: 139-153
16. McCullumsmith RE, Clinton SM, Meador-Woodruff JH: Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol 2004; 59: 19-45